Skip to main content
OpenTrials

Clinical trial condition

Follicular Lymphoma

Explore clinical trials studying Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

233 public trials 71 recruiting studies
Refine in advanced search Browse all conditions

Follicular Lymphoma trial results

Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

NCT05783609

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Icahn School of Medicine at Mount Sinai Hospital New York, United States
  • University of Rochester Medical Center Rochester, New York, United States
View Trial Details
Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Local Institution - 0225 Birmingham, Alabama, United States
  • Infirmary Cancer Care Mobile, Alabama, United States
  • Alaska Oncology and Hematology Anchorage, Alaska, United States
  • Local Institution - 0215 Little Rock, Arkansas, United States
View all 160 locations
View Trial Details
Recruiting

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

NCT07299149

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020 Tianjin, Tianjin Municipality, China
  • Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
View Trial Details
Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

NCT04989621

Conditions
Disease Attributes, Follicular Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Guangdong General Hospital Guangzhou, Guangdong, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
  • Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
View Trial Details
Recruiting

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265

Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
Locations
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
  • Rutgers Cancer Institute New Brunswick, New Jersey, United States
View Trial Details
Recruiting

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

NCT04998669

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Florida Cancer Specialists and Research Institute Fort Myers, Florida, United States
  • University of Miami Miami, Florida, United States
  • University of Michigan Ann Arbor, Michigan, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
View Trial Details

Related conditions